A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer

NCT07100106 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

285

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: GDC-4198
DRUG: Giredestrant
DRUG: Abemaciclib

Sponsor

Genentech, Inc.

Collaborators

[object Object]